← All trials

NCT04603807

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Apr 30, 2021
Primary completion
Jan 31, 2027
Completion date
Nov 30, 2027
First posted
Oct 27, 2020
Last posted
Nov 25, 2020
Enrollment
220
Arms / groups
2 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.